• Explore /
  • Poster
  • / A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.

A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.

Abstract Poster

Authors

null

Jing Huang

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Jing Huang , Yun Liu , Tao Wu , Zhen-yang Liu , Jin Zhou , Yuan Yuan , Mudan Yang , Bo Liu , Zhenbo Tan , Wu Zhuang , Jiayan Chen , Yanqing Liu , Haoyu Yu , Qingyu Wang , Jun Zhu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT05221658

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4029)

DOI

10.1200/JCO.2023.41.16_suppl.4029

Abstract #

4029

Poster Bd #

350

Abstract Disclosures

Similar Posters

First Author: Hideaki Bando

First Author: Manabu Muto

First Author: Takako Yoshii

First Author: A. Dimitrios Dimitrios Colevas